<DOC>
	<DOCNO>NCT02997150</DOCNO>
	<brief_summary>NIL-2 clinical trial design evaluate efficacy safety low dos Interleukin2 treatment recently diagnose , steroid dependent idiopathic nephrotic syndrome child . Recent data suggest Interleukin 2 could effective therapy via increase production regulatory T cell .</brief_summary>
	<brief_title>Treatment Steroid Dependent Idiopathic Nephrotic Syndrome Children With Low Doses Interleukin 2 : Pilot Study</brief_title>
	<detailed_description>The study include 10 child ( age : 3-15 year old ) . Patients receive low dos Interleukin 2 ( 0.5 million UI/m²/ injection , subcutaneously ) . The treatment initiated induction phase one injection per day 5 consecutive day , follow maintenance phase patient receive one injection every 14 day 6 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Nephrotic Syndrome</mesh_term>
	<mesh_term>Nephrosis</mesh_term>
	<mesh_term>Nephrosis , Lipoid</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Children 3 15 year age ( include ) steroid responsive idiopathic nephrotic syndrome Idiopathic nephrotic syndrome progress less 1 year Steroid dependent idiopathic nephrotic syndrome ( least 1 relapse steroid taper within 3 month withdrawal , reliance steroid &gt; 15 mg/m² every day ) Steroid dose inclusion 15 60 mg/m²every day Patient stable dose steroid within 8 day first injection IL2 Patient remission 15 day Patient affiliate French health insurance Signed consent parental authority Hypersensitivity IL2 one excipients Significant history presence cardiopathy Signs evolve infection require antibiotic treatment Respiratory distress , respiratory infection chronic respiratory failure Serious dysfunction one vital organ Leukocytes &lt; 4000/mm3 ; platelet &lt; 100 000/mm3 ; hematocrit &lt; 30 % Anomaly serum bilirubin creatinin level History organ allograft Other preexist autoimmune disease Male female pubescent teenager age 15 Male female teenager whose puberty begin one year Asthmatic patient Pregnant breastfeed female patient Participation another therapeutic trial concurrently 30 day prior inclusion</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Idiopathic nephrotic syndrome-child-steroid dependant-IL2</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>